Dr. med. Dennis Kannenkeril

Department of Medicine 4 – Nephrology and Hypertension

Copeptin levels in patients with treatment resistant hypertension before and six months after renal denervation (2019) Bosch A, Schmid A, Ott C, Kannenkeril D, Karg MV, Ditting T, Veelken R, et al. Journal article Evidence of neurodegeneration in individuals with only mildly elevated blood pressure (2019) Jung S, Bosch A, Kohler N, Ott C, Kannenkeril D, Dienemann T, Harazny JM, et al. Journal article Tissue sodium content in patients with type 2 diabetes mellitus (2019) Kannenkeril D, Karg MV, Bosch A, Ott C, Linz P, Nagel AM, Uder M, Schmieder R Journal article How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? (2018) Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder R Conference contribution COPEPTIN AS A RESEARCH MARKER IN CARDIOVASCULAR DISEASE (2018) Bosch A, Ott C, Schmid A, Kannenkeril D, Karg M, Ditting T, Veelken R, et al. Conference contribution DIFFERENT RESPONSE PATTERN TO AIRCRAFT NOISE EXPOSURE IN RENAL VERSUS SYSTEMIC HEMODYNAMIC (2018) Bosch A, Ott C, Kannenkeril D, Harazny JM, Striepe K, Karg M, Dienemann T, et al. Conference contribution THE INFLUENCE OF ANNOYANCE DUE TO NOISE ON RENAL HEMODYNAMIC (2018) Bosch A, Kannenkeril D, Ott C, Harazny JM, Striepe K, Karg M, Dienemann T, et al. Conference contribution Early vascular parameters in the micro- and macrocirculation in type 2 diabetes (2018) Kannenkeril D, Bosch A, Harazny J, Karg M, Jung S, Ott C, Schmieder R Journal article SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial (2018) Karg M, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, et al. Journal article Reduction of tissue sodium content by SGLT-2-inhibition with dapagliflozin (2017) Karg MV, Ott C, Linz P, Jumar A, Kannenkeril D, Titze J, Hammon M, et al. Conference contribution